

JUCESP PROTOCOLO
0.360.532/24-0



ALTHAIA S.A. INDÚSTRIA FAR

CNPJ/ME nº 48.344.725/0007-19

NIRE 35.300.525.892

**Ata de Reunião do Conselho de Administração
realizada em 07 de março de 2024**

DATA, HORA E LOCAL: Em 07 de março de 2024, às 14 horas, na sede da Althaia S.A. Indústria Farmacêutica ("Companhia"), localizada na Cidade de Atibaia, Estado de São Paulo, na Avenida Tégula, nº 888, Módulos 1, 15, 16, 17 e 21 Condomínio Centro Empresarial Atibaia, Bairro Ponte Alta, CEP 12952-820.

CONVOCAÇÃO E PRESENÇA: As formalidades de convocação foram dispensadas em face do comparecimento da totalidade dos membros do Conselho de Administração da Companhia.

MESA: Presidente: Cláudio Roberto Ely; Secretária: Priscila Maiochi da Cruz.

ORDEM DO DIA: Reuniram-se os membros do Conselho de Administração da Companhia para examinar, discutir e deliberar sobre: **(a)** a Distribuição Antecipada de Dividendos.


DELIBERAÇÕES: Instalada a reunião, após a análise e discussão da matéria constante da ordem do dia, os membros do Conselho de Administração decidiram, por unanimidade de votos e sem quaisquer ressalvas ou restrições, o quanto segue:

(a) Aprovar a distribuição antecipada de dividendos, referente ao resultado do exercício findo em 31 de dezembro de 2023 e "ad referendum" da Assembleia Geral Ordinária, que apreciar o balanço patrimonial e as demonstrações financeiras, referentes ao exercício social de 2023, ficando registrada à conta de adiantamento de dividendos, a ser liquidada na apuração total dos dividendos do exercício de 2023, aos seus acionistas, na forma do art. 38 do Estatuto Social e no valor correspondente a R\$ 14.300.000,00 (quatorze milhões e trezentos mil reais). Os dividendos serão pagos, sem atualização monetária, a partir da data desta deliberação.

DS
CRE

DS
PMDC

ENCERRAMENTO E LAVRATURA DA ATA: Nada mais havendo a ser tratado, foi oferecida a palavra a quem dela quisesse fazer uso e, como ninguém se manifestou, foram encerrados os trabalhos pelo tempo necessário à lavratura da presente ata, a qual, após reaberta a sessão, foi lida, aprovada e assinada por todos os presentes.



ASSINATURAS: Mesa: Presidente: Cláudio Roberto Ely; e Secretária: Priscila Maiochi da Cruz.
Conselheiros Presentes: Jairo Aparecido Yamamoto, Aline Aparecida Yamamoto Zampieri, Herbert Cesar Gonçalves, Gregor Rodrigues Martins Einsiedler e Cláudio Roberto Ely.

CERTIDÃO: Certifico que a presente ata é cópia fiel da original lavrada em livro próprio.

Atibaia, 07 de março de 2024

MESA:

DocuSigned by:
Cláudio Roberto Ely
737940D4710E4C7

Cláudio Roberto Ely
Presidente da Mesa

DocuSigned by:
PRISCILA MAIOCHI DA CRUZ
D4957BCD6E67446

Priscila Maiochi da Cruz
Secretária da Mesa



Certificado de Conclusão

Identificação de envelope: DE1181D11CB349D3848E83D54C98EDCA
 Assunto: DocuSign: 17ª Ata da RCA_Distribuição Antecipada de Dividendos_07.03.2024
 Envelope fonte:
 Documentar páginas: 2
 Assinar páginas: 5
 Assinatura guiada: Ativado
 Selo com EnvelopeId (ID do envelope): Ativado
 Fuso horário: (UTC-03:00) Brasília

Status: Concluído

Remetente do envelope:
 Priscila Maiochi da Cruz
 AV TEGULA, 888, EDIF TOPAZIO MODULO 15
 Atibaia, 12.952-820
 priscila.cruz@althaia.com.br
 Endereço IP: 200.232.72.10

Rastreamento de registros

Status: Original
 07/03/2024 15:29:14

Portador: Priscila Maiochi da Cruz
 priscila.cruz@althaia.com.br

Local: DocuSign

Eventos do signatário

Claudio Roberto Ely
 claudiorely@gmail.com
 Nível de segurança: E-mail, Autenticação da conta (Nenhuma)

Assinatura

DocuSigned by:
 Claudio Roberto Ely
 737940D4710E4C7...

Adoção de assinatura: Estilo pré-selecionado
 Usando endereço IP: 187.108.38.186

Registro de hora e data

Enviado: 07/03/2024 15:35:48
 Visualizado: 07/03/2024 15:40:50
 Assinado: 07/03/2024 15:41:47

Termos de Assinatura e Registro Eletrônico:

Aceito: 07/03/2024 15:40:50
 ID: 038796b7-3b14-4f89-9acb-853a059014e9

PRISCILA MAIOCHI DA CRUZ
 priscila.cruz@althaia.com.br
 Gerente Jurídico
 ALTHAIA S.A. INDUSTRIA FARMACEUTICA
 Nível de segurança: E-mail, Autenticação da conta (Nenhuma)

DocuSigned by:
 PRISCILA MAIOCHI DA CRUZ
 D4957BCD8E67446...

Adoção de assinatura: Estilo pré-selecionado
 Usando endereço IP: 200.232.72.10

Enviado: 07/03/2024 15:35:48
 Visualizado: 07/03/2024 15:36:02
 Assinado: 07/03/2024 15:36:30

Termos de Assinatura e Registro Eletrônico:

Não oferecido através do DocuSign

Eventos do signatário presencial

Assinatura

Registro de hora e data

Eventos de entrega do editor

Status

Registro de hora e data

Evento de entrega do agente

Status

Registro de hora e data

Eventos de entrega intermediários

Status

Registro de hora e data

Eventos de entrega certificados

Status

Registro de hora e data

Eventos de cópia

Status

Registro de hora e data

Eventos com testemunhas

Assinatura

Registro de hora e data

Eventos do tabelião

Assinatura

Registro de hora e data

Eventos de resumo do envelope

Status

Carimbo de data/hora

Envelope enviado
 Entrega certificada
 Assinatura concluída

Com hash/criptografado
 Segurança verificada
 Segurança verificada

07/03/2024 15:35:49
 07/03/2024 15:36:02
 07/03/2024 15:36:30

Eventos de resumo do envelope

Concluído

Eventos de pagamento

Termos de Assinatura e Registro Eletrônico



Carimbo de data/hora

07/03/2024 15:41:47

Carimbo de data/hora

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, ALTHAIA S.A. INDUSTRIA FARMACEUTICA (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact ALTHAIA S.A. INDUSTRIA FARMACEUTICA:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To advise ALTHAIA S.A. INDUSTRIA FARMACEUTICA of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at ALTHAIA@ALTHAIA.COM and in the body of such request you must state: your previous email address, your new email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from ALTHAIA S.A. INDUSTRIA FARMACEUTICA

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to ALTHAIA@ALTHAIA.COM and in the body of such request you must state your email address, full name, mailing address, and telephone number.

To withdraw your consent with ALTHAIA S.A. INDUSTRIA FARMACEUTICA

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;

ii. send us an email to ALPHA@ALPHA.COM and in the body of such request you must state your email, full name, mailing address, and telephone number. . .

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: <https://support.docusign.com/guides/signer-guide-signing-system-requirements>.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

By selecting the check-box next to 'I agree to use electronic records and signatures', you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify ALTHAIA S.A. INDUSTRIA FARMACEUTICA as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by ALTHAIA S.A. INDUSTRIA FARMACEUTICA during the course of your relationship with ALTHAIA S.A. INDUSTRIA FARMACEUTICA.